UnknownPhase 2

A Study of CM310 in Subjects With Chronic Pruritus

50 participantsStarted 2022-08-30

Plain-language summary

This is a multi-center, randomized, double blind, placebo-controlled Phase II study to evaluate the efficacy and safety of CM310 in subjects with chronic pruritus of unknown origin.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Age ≥ 18 years old. * With chronic pruritus of unknown origin. * With the worst pruritus numerical rating scale (WI-NRS) ≥7. * Contraception. Exclusion Criteria: * Heavy drinking in the 3 months prior to screening. * With severe hepatic and renal impairment. * Previous history of autosensitivity dermatitis. * Allergic to CM310/placebo. * Vaccination with live attenuated vaccine within 12 weeks before randomization or during the planned study period.

What they're measuring

Percentage change of weekly average in the worst itching numerical rating scale (WI-NRS)

Timeframe: at week 16

Trial details

NCT IDNCT05452343

SponsorKeymed Biosciences Co.Ltd

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-03-01

View on ClinicalTrials.gov More Chronic Pruritus of Unknown Origin trials